Digital Breast Tomosynthesis Market
The market for Digital Breast Tomosynthesis was estimated at $3.2 billion in 2024; it is anticipated to increase to $6.5 billion by 2030, with projections indicating growth to around $11.9 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Digital Breast Tomosynthesis Market Outlook
Revenue, 2024
$3.2B
Forecast, 2034
$10.5B
CAGR, 2025 - 2034
12.7%
The Digital Breast Tomosynthesis industry revenue is expected to be around $3.6 billion in 2025 and expected to showcase growth with 12.7% CAGR between 2025 and 2034.
DBM refers to state of the art technology that produces images of different layers of breast tissue to offer in depth information to radiologists. An evident shift in the DBM sector is its growing presence in institutions worldwide because of its proven effectiveness, in enhancing the detection rates of cancer.
Market Key Insights
- The Digital Breast Tomosynthesis market is projected to grow from $3.2 billion in 2024 to $10.5 billion in 2034. This represents a CAGR of 12.7%, reflecting rising demand across Early Detection of Breast Cancer, Routine Screening and Follow-up Evaluation after Cancer Treatment.
- Hologic, GE Healthcare, Fujifilm Holdings Corporation are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Digital Breast Tomosynthesis market and are expected to observe the growth CAGR of 11.4% to 15.2% between 2024 and 2030.
- Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 8.9% to 13.3%.
- Transition like Emerging AI Integration is expected to add $362 million to the Digital Breast Tomosynthesis market growth by 2030.
- The Digital Breast Tomosynthesis market is set to add $7.4 billion between 2024 and 2034, with manufacturer targeting Diagnostic Centers & Others End-User projected to gain a larger market share.
- With
rising prevalence of breast cancer, and
technological advancements in medical imaging, Digital Breast Tomosynthesis market to expand 231% between 2024 and 2034.
Opportunities in the Digital Breast Tomosynthesis
The field of healthcare has also been gaining attention lately with a focus, on delivering individualized patient care.
Growth Opportunities in North America and Europe
In North America the market for Digital Breast Tomosynthesis is fiercely competitive and well developed because of the embrace of cutting edge medical technologies and the presence of top manufacturers in the region. The higher occurrence of breast cancer and investments in healthcare infrastructure also play a role in driving market demand. The availability of insurance coverage, for DBT examinations additionally fuels growth in this market.
In Europe's DBT market growth is fueled by the growing focus on detecting breast cancer and the strong healthcare system in the region benefiting from technological progress in DBT and active participation of major players. Nevertheless challenges may arise due to the costs of DBT equipment and the need for trained experts. Nonetheless there are prospects in markets, within Europe.
Market Dynamics and Supply Chain
01
Driver: Rising Prevalence of Breast Cancer, and Increase in Healthcare Spending
The rise in breast cancer instances is also fueling the interest, in Digital Breast Tomosynthesis . The invasive approach of DBS makes it a preferred screening option that allows for early detection and enhances survival rates. The rise in healthcare spending by both governments and individuals has also resulted in enhanced availability of advanced diagnostic technologies such, as DBT with a notable portion of this investment dedicated to medical imaging devices that contribute to the expansion of the DBT market.
Advancements in medical imaging technology have also continually pushed the DBT market ahead well The incorporation of AI, into DBT has also enhanced its effectiveness even more by aiding in accurate detection and diagnosis.
02
Restraint: High Installation and Maintenance Cost
The high cost of acquiring and maintaining Digital Breast Tomosynthesis (DBT) machines remains a key restraint for market growth. The advanced imaging technology integrated into these systems significantly elevates their price, posing a major financial burden for healthcare providers, especially in low- and middle-income countries. Additionally, ongoing maintenance and operational expenses further increase the total cost of ownership, making widespread adoption challenging for hospitals and diagnostic centers.
03
Opportunity: Integration of AI into DBT and Extension to Rural and Remote Areas
The use of AI and ML techniques in the field of imaging holds a lot of potential by improving the precision and speed of diagnoses it offers. At present the utilization of AI in Digital Breast Tomosynthesis is not only widespread. Presents a new opening, for development. Introducing AI into this domain has the potential to improve image analysis significantly by identifying patterns that are hard to detect and enhancing the accuracy of breast cancer diagnosis.
Digital Breast Tomosynthesis has greatly benefited the healthcare sector by offering 3D mammographic images that enhance diagnostic capabilities significantly. Nevertheless there exists an untapped market in rural and remote areas across many countries, where access, to cutting edge medical technology remains scarce. Introducing DBT to these underserved regions can address a pressing demand making diagnostic services more reachable and notably enhancing results.
04
Challenge: Regulatory Hurdles
Stringent regulations concerning the approval and promotion of devices may hinder the expansion of the DBT market as well. There are standards and procedures in place, by healthcare regulatory agencies globally to ensure patient safety when it comes to the endorsement of new medical devices.
Supply Chain Landscape
1
Raw Material Acquisition
Mitsubishi ChemicalDuPont
2
Component Manufacturing
Hitachi MetalsSamsung
3
Assembly & Testing
GE HealthcareSiemens Healthineers
4
Application & End-User
HospitalsDiagnostic CentersBreast Cancer Screening Programs
1
Raw Material Acquisition
Mitsubishi ChemicalDuPont
2
Component Manufacturing
Hitachi MetalsSamsung
3
Assembly & Testing
GE HealthcareSiemens Healthineers
4
Application & End-User
HospitalsDiagnostic CentersBreast Cancer Screening Programs
Use Cases of Digital Breast Tomosynthesis in Early Detection of Cancer & Routine Screening
Early Detection of Breast Cancer : Digital Breast Tomosynthesis is mainly utilized for detecting breast cancer at a stage using its three dimensional images that offer detailed layers of the breast structure to improve the precision of cancer detection and reduce false positive diagnoses significantly. The leading players in the market, like Hologic and GE Healthcare rely heavily on this technology to deliver diagnostic services.
Routine Screening : In breast screening procedures DBT plays a crucial role by offering a more comprehensive view compared to conventional mammography. Its enhanced capabilities enable the detection of a range of breast conditions and tumors. Siemens Healthineers and Fujifilm are leading providers of this service.
Follow-up Evaluation after Cancer Treatment : DBTs are also used in assessments following cancer therapy providing detailed imaging that enables medical professionals to track the impact of treatment and identify potential relapses early on in the process of recovery post cancer treatment phase transition periods companies, like Canon Medical Systems and Planmed play significant roles in utilizing DBTs for this critical aspect of cancer care.
Recent Developments
DBT also referred to as 3D mammographys experiencing a surge in popularity and acceptance in current market trends with its advanced features proving invaluable in detecting and treating breast cancer early to significantly enhance patient outcomes. Due, to the recognized potential of DBT technology many healthcare organizations are reallocating their resources and investments to embrace this approach.
December 2024 : Siemens Healthineers has introduced a Digital Breast Tomosynthesis system that comes with advanced AI features aimed at enhancing detection accuracy and minimizing patient discomfort.
October 2024 : The new3D mammography scanner from Hologic Inc has been given the light by the FDA; its set to revolutionize image clarity and scanning efficiency, in Digital Breast Tomosynthesis.
July 2024 : GE Healthcare revealed their intentions to expand with their Digital Breast Tomosynthesis offerings following the completion of successful trials, in North America and Europe.
Impact of Industry Transitions on the Digital Breast Tomosynthesis Market
As a core segment of the Medical Device industry,
the Digital Breast Tomosynthesis market develops in line with broader industry shifts.
Over recent years, transitions such as Emerging AI Integration and Adoption of Telehealth have redefined priorities
across the Medical Device sector,
influencing how the Digital Breast Tomosynthesis market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Emerging AI Integration
The combination of AI and Digital Breast Tomosynthesis has brought about a shift in the field. Tools powered by AI have the potential to enhance the efficiency and precision of DBT interpretations leading to results for patients. This transformation is fundamentally changing how healthcare providers utilize DBT in their work moving towards advanced AI supported approaches, for diagnosing and planning treatments.
02
Adoption of Telehealth
The DBT market is experiencing another shift due, to the widespread embrace of telehealth brought about by the COVID‐19 pandemic.